Cancer Immunology Research · 2016 · 249 citations · 55 references
MedicineImmunologyOncologyCancer ImmunologyTumor ImmunologyTumor MicroenvironmentCancer Cell SignalingChemokine NetworksChemokine SignalingImmune Cell SignalingNeutrophil BiologyPancreatic CancerC-c Chemokine Receptor 2 SignalingCancer-associated NeutrophilsImmunosuppressive MicroenvironmentNeutrophil ReceptorsNf-κb SignalingT-cell Mediated ImmunityTumor Progression MicroenvironmentTumor-associated Neutrophils
Tumor-associated neutrophils are increasingly recognized for their ability to promote tumor progression, mediate resistance to therapy, and regulate immunosuppression. Evidence from various murine models has shown that the chemokine receptor CXCR2 attracts neutrophil into tumors and, therefore, represents a tractable therapeutic target. Here, we report prominent expression of a neutrophil gene signature in a subset of human pancreatic adenocarcinoma (PDA). CXCL5 was the most prominently expressed CXCR2 ligand in human PDA, and its expression was higher in PDA than in any other common tumor represented in The Cancer Genome Atlas. Using a genetically engineered mouse model of PDA, we found that tumor and stromal cells differentially expressed CXCR2 ligands, with Cxcl5 high in tumor and Cxcl2 high in stroma. Cxcl5 expression was associated with mutant Kras expression and regulated by NF-κB activation. Host CXCR2 inhibition by genetic ablation prevented neutrophil accumulation in pancreatic tumors and led to a T cell-dependent suppression of tumor growth. In the absence of neutrophils, activated and functional T cells infiltrated pancreatic tumors otherwise devoid of effector T cells. Thus, the CXCR2-ligand axis helps establish an immunosuppressive microenvironment in PDA, highlighting the potential utility of targeting this axis as a novel therapy for this deadly disease. Cancer Immunol Res; 4(11); 968-82. ©2016 AACR.
55
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2016 · 16.2K citations · Full text
The Cancer Genome Atlas Pan-Cancer analysis project
John N. Weinstein, Gordon B. Mills, Kenna Shaw et al. · Nature Genetics · 2013 · 9.5K citations · Full text
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy, Françoise Desseigne, Marc Ychou et al. · New England Journal of Medicine · 2011 · 7.8K citations · Full text
Medicine, Oncology, Pharmacology +13